$ARWR -66% on bad news. Arrowhead to focus resou
Post# of 22755
Arrowhead to focus resources on subcutaneous and extra-hepatic RNAi therapeutics; three clinical-stage drug candidates axed; 30% of workforce cut; shares down 2% after hours
http://seekingalpha.com/news/3227473-arrowhea...ical-stage